<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36815691</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Keeping expanded access programs in context.</ArticleTitle><Pagination><StartPage>337</StartPage><EndPage>338</EndPage><MedlinePgn>337-338</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27802</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caress</LastName><ForeName>James B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-5814-6083</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Muscle Nerve. 2023 May;67(5):354-362</RefSource><PMID Version="1">36533976</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FDA approval</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">expanded access program</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36815691</ArticleId><ArticleId IdType="doi">10.1002/mus.27802</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Jerome RN, Edwards TL, Boswell HC, Bernard GR, Harris PA, Pulley JM. Recommendations to facilitate expanded access to investigational therapies for seriously ill patients. Acad Med. 2016;91:305-309.</Citation></Reference><Reference><Citation>Speers MA. Providing patients with critical or life-threatening illnesses access to experimental drug therapy: a guide to clinical trials and the US FDA expanded access program. Pharm Med. 2019;33:89-98.</Citation></Reference><Reference><Citation>1 USC 321, 331, 351, 352, 353,355 360bbb, 371; 42 USC 262. Subpart I-expanded access to investigational drugs for treatment use. Updated November 29, 2022. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&amp;showFR=1&amp;subpartNode=21:5.0.1.1.3.9. Accessed December 27, 2022.</Citation></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505-512.</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919-930.</Citation></Reference><Reference><Citation>Sabatelli M, Zollino M, Luigetti M, et al. Uncovering amyotrophic lateral sclerosis phenotypes: clinical features and long-term follow-up of upper motor neuron-dominant ALS. Amyotroph Lateral Scler. 2011;12:278-282.</Citation></Reference><Reference><Citation>Yerton M, Winter A, Kostov A, et al. An expanded access protocol of RT001 in amyotrophic lateral sclerosis-initial experience with a lipid peroxidation inhibitor. Muscle Nerve. 2022;66:421-425.</Citation></Reference><Reference><Citation>Gelevski D, Addy G, Rohrer M, et al. Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: experience with expanded access protocol. Muscle Nerve. 2023;67:354-362.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>